ZA202210628B - Antibodies binding il4r and uses thereof - Google Patents

Antibodies binding il4r and uses thereof

Info

Publication number
ZA202210628B
ZA202210628B ZA2022/10628A ZA202210628A ZA202210628B ZA 202210628 B ZA202210628 B ZA 202210628B ZA 2022/10628 A ZA2022/10628 A ZA 2022/10628A ZA 202210628 A ZA202210628 A ZA 202210628A ZA 202210628 B ZA202210628 B ZA 202210628B
Authority
ZA
South Africa
Prior art keywords
il4r
antibodies binding
antibodies
binding
binding il4r
Prior art date
Application number
ZA2022/10628A
Other languages
English (en)
Inventor
Chen Mingjiu
Tan Wei
Xiaoyan Zhong Cathy
Zhiqing Ma Mark
Xia Shukai
Zhang Zhengping
Xu Hongjiang
Lu Zhijian
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of ZA202210628B publication Critical patent/ZA202210628B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2022/10628A 2020-02-27 2022-09-26 Antibodies binding il4r and uses thereof ZA202210628B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982521P 2020-02-27 2020-02-27
PCT/CN2021/077784 WO2021170020A1 (en) 2020-02-27 2021-02-25 Antibodies binding il4r and uses thereof

Publications (1)

Publication Number Publication Date
ZA202210628B true ZA202210628B (en) 2025-01-29

Family

ID=75108091

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/10628A ZA202210628B (en) 2020-02-27 2022-09-26 Antibodies binding il4r and uses thereof

Country Status (12)

Country Link
US (1) US20230105029A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110816A1 (cg-RX-API-DMAC7.html)
JP (2) JP7711079B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220147642A (cg-RX-API-DMAC7.html)
CN (4) CN119708230A (cg-RX-API-DMAC7.html)
AU (1) AU2021228061A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017174A2 (cg-RX-API-DMAC7.html)
CA (1) CA3169479A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022010665A (cg-RX-API-DMAC7.html)
TW (1) TWI859419B (cg-RX-API-DMAC7.html)
WO (1) WO2021170020A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210628B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025217A1 (zh) * 2021-08-26 2023-03-02 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
WO2023235738A1 (en) * 2022-06-02 2023-12-07 Eli Lilly And Company Human interleukin-4 receptor alpha antibody glucocorticoid conjugates
KR20240038841A (ko) * 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
CA3268111A1 (en) * 2022-09-22 2024-03-28 Biosion Inc. Recombinant bispecific antibodies targeting TSLP and IL4R
WO2025026332A1 (zh) * 2023-08-01 2025-02-06 先声药业有限公司 抗il4r抗体及其应用
CN117924490B (zh) * 2023-12-22 2024-10-22 华润生物医药有限公司 抗il-4r抗体及其用途
CN117924491B (zh) * 2023-12-22 2024-10-18 华润生物医药有限公司 抗il-4r抗体及其用途
US20250388685A1 (en) 2024-04-15 2025-12-25 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
US20260070995A1 (en) 2024-09-09 2026-03-12 Marcella Ruddy Methods for treating bullous pemphigoid by administering an il-4r antagonist
WO2026059949A1 (en) 2024-09-10 2026-03-19 Sanofi Biotechnology Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
WO2026123121A1 (en) * 2024-12-11 2026-06-18 Zymeworks Bc Inc. Anti-il-4r.alpha. antibody constructs and methods of use
WO2026151982A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9108652D0 (en) 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU686113B2 (en) 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
JP3919830B2 (ja) 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−1組換え抗体および該抗体をコードする遺伝子断片
WO1995018634A1 (en) 1994-01-04 1995-07-13 The Scripps Research Institute Human monoclonal antibodies to herpes simplex virus and methods therefor
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9814383D0 (en) 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
JP4593783B2 (ja) 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗c型肝炎ウイルス抗体およびその使用
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
UA93653C2 (ru) * 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
BRPI0510909A2 (pt) 2004-05-19 2008-12-16 Medarex Inc composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
CA2598454C (en) 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EA016577B1 (ru) 2005-09-26 2012-06-29 Медарекс, Инк. Конъюгаты антитело-лекарство и их применение
BRPI0619331A2 (pt) 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
CA2664343C (en) * 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
TWI412367B (zh) 2006-12-28 2013-10-21 梅達雷克斯有限責任公司 化學鏈接劑與可裂解基質以及其之綴合物
JP2010519310A (ja) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
WO2009121847A2 (en) * 2008-04-02 2009-10-08 Apogenix Gmbh Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
US8980273B1 (en) * 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) * 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
CN108409860B (zh) * 2017-02-10 2021-10-15 三生国健药业(上海)股份有限公司 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用

Also Published As

Publication number Publication date
US20230105029A1 (en) 2023-04-06
JP2023515223A (ja) 2023-04-12
AU2021228061A1 (en) 2022-10-13
MX2022010665A (es) 2022-09-23
BR112022017174A2 (pt) 2022-10-18
WO2021170020A1 (en) 2021-09-02
TW202140564A (zh) 2021-11-01
EP4110816A1 (en) 2023-01-04
CN115087673B (zh) 2025-02-18
KR20220147642A (ko) 2022-11-03
JP7711079B2 (ja) 2025-07-22
TWI859419B (zh) 2024-10-21
CN115087673A (zh) 2022-09-20
JP2025157317A (ja) 2025-10-15
CN119708231A (zh) 2025-03-28
CN119859187A (zh) 2025-04-22
CA3169479A1 (en) 2021-09-02
CN119708230A (zh) 2025-03-28

Similar Documents

Publication Publication Date Title
IL308808A (en) Antibodies against CCR8 and their uses
EP4025602A4 (en) TSLP BINDING ANTIBODIES AND USES THEREOF
GB202017058D0 (en) Antibodies and uses thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
IL319931A (en) Anti-CD122 antibodies and their uses
IL310662A (en) Anti-CD161 antibodies and their uses
IL307940A (en) Anti-ADGRE2 antibodies and their uses
EP4013789A4 (en) VISTA BINDING ANTIBODIES AND USES THEREOF
EP4041772A4 (en) 4-1BB-BINDING ANTIBODIES AND USES THEREOF
IL304681A (en) psma binding proteins and uses thereof
EP4161964A4 (en) LAG3-BINDING ANTIBODIES AND USES THEREOF
IL315438A (en) New anti-CD3 antibodies and their uses
IL310810A (en) Anti-ACVR2A antibodies and uses thereof
IL277969A (en) Antibodies that bind 1-PD and uses thereof
IL327202A (en) Anti-CDH17 antibodies and their uses
IL317391A (en) Novel anti-LILRB4 antibodies and their uses
HRP20260098T1 (hr) Anti-gprc5d monoklonska protutijela i njihova upotreba
EP4165082A4 (en) TNFR2-BINDING ANTIBODIES AND USES THEREOF
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
IL316176A (en) SIGLEC-8 binding proteins and their uses
IL304412A (en) Antibodies against cd112r and uses thereof
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
IL306082A (en) TROP2 binding antibodies and their uses
EP4308604A4 (en) PD-L1-BINDING ANTIBODIES AND USES THEREOF
IL312584A (en) ANTI-VISTA antibodies and their uses